Mizuho Downgrades Amylyx to Neutral After Disappointing ALS Trial Results
Monday, 18 March 2024, 13:35
Mizuho downgrades Amylyx to Neutral following recent developments.
Mizuho Securities has revised its rating on Amylyx Pharmaceuticals from Buy to Neutral, expressing concerns over the company's ALS trial results. This downgrade is based on the disappointing outcome of the recent clinical trial on ALS treatment.
Key Points:
- Mizuho downgrade: From Buy to Neutral
- Reason: Disappointing ALS trial results
- Price target lowered to $4
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.